Teleflex Management

Management criteria checks 3/4

Teleflex's CEO is Liam Kelly, appointed in May 2016, has a tenure of 8.5 years. total yearly compensation is $9.04M, comprised of 11.7% salary and 88.3% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth €5.01M. The average tenure of the management team and the board of directors is 4.6 years and 6.8 years respectively.

Key information

Liam Kelly

Chief executive officer

US$9.0m

Total compensation

CEO salary percentage	11.7%
CEO tenure	8.5yrs
CEO ownership	0.06%
Management average tenure	4.6yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Liam Kelly's remuneration changed compared to Teleflex's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 29 2024	n/a	n/a	US$238m
Jun 30 2024	n/a	n/a	US$265m
Mar 31 2024	n/a	n/a	US$296m
Dec 31 2023	US$9m	US$1m	US$358m
Oct 01 2023	n/a	n/a	US$405m
Jul 02 2023	n/a	n/a	US$369m
Apr 02 2023	n/a	n/a	US$363m
Dec 31 2022	US$8m	US$1m	US$363m
Sep 25 2022	n/a	n/a	US$412m
Jun 26 2022	n/a	n/a	US$510m
Mar 27 2022	n/a	n/a	US$488m
Dec 31 2021	US$9m	US$982k	US$485m
Sep 26 2021	n/a	n/a	US$434m
Jun 27 2021	n/a	n/a	US$351m
Mar 28 2021	n/a	n/a	US$280m
Dec 31 2020	US$6m	US$943k	US$336m
Sep 27 2020	n/a	n/a	US$367m
Jun 28 2020	n/a	n/a	US$479m
Mar 29 2020	n/a	n/a	US$551m
Dec 31 2019	US$7m	US$869k	US$462m
Sep 29 2019	n/a	n/a	US$442m
Jun 30 2019	n/a	n/a	US$269m
Mar 31 2019	n/a	n/a	US$183m
Dec 31 2018	US$6m	US$846k	US$196m
Sep 30 2018	n/a	n/a	US$66m
Jul 01 2018	n/a	n/a	US$89m
Apr 01 2018	n/a	n/a	US$170m
Dec 31 2017	US$3m	US$617k	US$155m

Compensation vs Market: Liam's total compensation ($USD9.04M) is above average for companies of similar size in the German market ($USD3.63M).

Compensation vs Earnings: Liam's compensation has been consistent with company performance over the past year.

CEO

Liam Kelly (57 yo)

8.5yrs

Tenure

US$9,039,947

Compensation

Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. He serves as Independent Director of Enovis Corporation (form...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Liam Kelly	Chairman	8.5yrs	US$9.04m	0.060% € 5.0m
Thomas Powell	Executive VP & CFO	12.7yrs	US$3.53m	0.023% € 1.9m
Daniel Logue	Corporate VP	3.8yrs	US$1.81m	0.021% € 1.8m
Jay White	Corporate VP & President of Global Commercial	3.8yrs	US$2.37m	0.0071% € 589.6k
John Deren	Corporate VP & Chief Accounting Officer	7.5yrs	no data	0.0043% € 354.6k
Timothy Duffy	VP & Chief Information Officer	no data	no data	no data
Howard Cyr	Corporate VP & Chief Compliance Officer	3yrs	no data	no data
Cameron Hicks	Corporate VP & Chief Human Resources Officer	11.6yrs	US$1.34m	0.016% € 1.4m
James Ferguson	President & GM of Surgical	no data	no data	no data
Michelle Fox	Corporate VP & Chief Medical Officer	4.8yrs	no data	no data
Matthew James	President	4.4yrs	no data	no data
Jake Newman	President of The Americas	3.8yrs	no data	no data

4.6yrs

Average Tenure

57yo

Average Age

Experienced Management: TBH's management team is considered experienced (4.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Liam Kelly	Chairman	6.5yrs	US$9.04m	0.060% € 5.0m
John Heinmiller	Independent Director	5.8yrs	US$308.20k	0.0061% € 503.3k
Gretchen Frances Haggerty	Independent Director	8.2yrs	US$308.20k	0.0077% € 639.4k
Stuart Randle	Independent Director	15.5yrs	US$324.53k	0.010% € 867.0k
Andrew Krakauer	Independent Director	6.8yrs	US$303.28k	0.0085% € 706.7k
Stephen Klasko	Independent Lead Director	16.5yrs	US$350.30k	0.029% € 2.4m
Candace Duncan	Independent Director	9.5yrs	US$331.70k	0.0076% € 631.1k
Jaewon Ryu	Independent Director	1.5yrs	US$364.30k	no data
Neena Patil	Independent Director	2.6yrs	US$301.20k	0.00086% € 71.4k

6.8yrs

Average Tenure

68yo

Average Age

Experienced Board: TBH's board of directors are considered experienced (6.8 years average tenure).

Teleflex Management

Management criteria checks 3/4

Key information

Recent management updates

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Insufficient new directors

Insufficient new directors

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Insufficient new directors

Recent updates

Third quarter dividend of US$0.34 announced

Teleflex Incorporated Revises Earnings Guidance for the Year 2024

Third quarter 2024 earnings released: EPS: US$2.37 (vs US$2.93 in 3Q 2023)

Teleflex Incorporated Announces Quarterly Dividend, Payable December 16, 2024

Teleflex Incorporated Announces First Patient Enrolled Barrigel™ Rectal Spacer Trial for Post Radical Prostatectomy Radiation Therapy

Teleflex Incorporated Launches Next-Generation Arrow VPS Rhythm DLX Device and NaviCurve Stylet in Canada

Teleflex Incorporated Announces the Presentation of Data Supporting the Safety and Efficacy of Barrigel Rectal Spacer

Second quarter dividend of US$0.34 announced

Second quarter 2024 earnings released: EPS: US$1.70 (vs US$2.37 in 2Q 2023)

Teleflex Incorporated (NYSE:TFX) announces an Equity Buyback for $500 million worth of its shares.

Teleflex Incorporated Revises Earnings Guidance for the Full Year 2024

Teleflex Incorporated Expands Intraosseous Vascular Access Portfolio with New Arrow™ EZ-IO™ Intraosseous Access Procedure Tray

First quarter dividend of US$0.34 announced

Teleflex Incorporated Announces Quarterly Cash Dividend, Payable on June 14, 2024

Teleflex Incorporated Raises Earnings Guidance for the Full Year 2024

First quarter 2024 earnings released: EPS: US$0.33 (vs US$1.65 in 1Q 2023)

Teleflex Incorporated, Annual General Meeting, May 03, 2024

Fourth quarter dividend of US$0.34 announced

Full year 2023 earnings released: EPS: US$7.61 (vs US$7.74 in FY 2022)

Teleflex Incorporated Announces Quarterly Dividend, Payable on March 15, 2024

Teleflex Incorporated Offers Its Titan SGS Stapler with Staple Line Reinforcement

Teleflex Incorporated Announces First Patient Enrollment in ACCESS-MANTA Registry

Teleflex Incorporated Announces A New Peer-Reviewed Study in the Nature Journal Prostate Cancer and Prostatic Diseases Confirms the Position of the UroLift System as the Gold Standard in Minimally Invasive Surgical Treatment

Teleflex Incorporated Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$2.93 (vs US$2.17 in 3Q 2022)

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated (NYSE:TFX) acquired Palette Life Sciences for $650 million.

Teleflex Incorporated Announces Extension of Arrow ErgoPack Complete System to Hemodialysis and Large Bore Central Venous Catheters

Upcoming dividend of US$0.34 per share at 0.6% yield

Teleflex Incorporated Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$2.37 (vs US$2.25 in 2Q 2022)

Teleflex Incorporated Receives FDA Clearance for Expanded Indication for QuikClot Control+(TM) Hemostatic Device Usage in Cardiac Surgical Procedures

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB for $650 million.

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Palette Life Sciences AB from Östersjöstiftelsen, Endowment Arm, Praktikerinvest AB and Recipharm Venture Fund AB for $650 million.

Teleflex Incorporated Receives FDA Clearance for the Wattson Temporary Pacing Guidewire

Teleflex Incorporated Announces the Arrow(R) EZ-Io(R) Needle Is Now FDA Cleared for Use in an MRI Environment

Teleflex Announces Quarterly Dividend, June 15, 2023

Teleflex Incorporated Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$1.65 (vs US$1.65 in 1Q 2022)

Full year 2022 earnings released: EPS: US$7.74 (vs US$10.37 in FY 2021)

Insufficient new directors

Upcoming dividend of US$0.34 per share

Teleflex Incorporated Announces Worldwide Recall of Affected Lots of Gibeck Iso-Gard Filter Products

Third quarter 2022 earnings released: EPS: US$2.17 (vs US$4.26 in 3Q 2021)

Teleflex Incorporated Revises Earnings Guidance for the Year 2022

Teleflex Incorporated (NYSE:TFX) completed the acquisition of Standard Bariatrics, Inc.

Teleflex Incorporated Launches New Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex Incorporated (NYSE:TFX) entered into a definitive agreement to acquire Standard Bariatrics, Inc. for $300 million.

Upcoming dividend of US$0.34 per share

Second quarter 2022 earnings released: EPS: US$2.25 (vs US$1.78 in 2Q 2021)

Teleflex Incorporated Provides Earnings Guidance for the Full Year of 2022

Teleflex Incorporated (NYSE:TFX) acquired unknown stake in Traverse Vascular Inc.

Teleflex Incorporated Announces First Patient Enrollment in MANTA Ultra Study

Teleflex Launches New Arrow Pressure Injectable Midline Catheter in Australia and New Zealand

Teleflex Incorporated Launches New Arrow Pressure Injectable Midline Catheter in Europe, the Middle East and Africa Region

Teleflex Incorporated Reaffirms Earnings Guidance for the Full Year of 2022

Teleflex Incorporated Announces Regulatory Clearance for Its Urolift® System in China for the Treatment of Benign Prostatic Hyperplasia

Teleflex Announces Health Canada Approval of MANTA® Vascular Closure Device

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable on June 15, 2022

First quarter 2022 earnings released: EPS: US$1.65 (vs US$1.60 in 1Q 2021)

Insufficient new directors

Teleflex Announces the Launch of the UroLift® System in Japan for the Treatment of Benign Prostatic Hyperplasia

Teleflex Incorporated, Annual General Meeting, Apr 29, 2022

Teleflex Incorporated Announces Board Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Teleflex Incorporated Declares Quarterly Cash Dividend, Payable March 15, 2022

Teleflex Receives FDA Clearance for Expanded Indication for Specialty Catheter and Coronary Guidewire Use in CTO PCI Procedures

Insufficient new directors

Independent Director recently bought €273k worth of stock